Management of hepatitis C genotype 4 in the directly acting antivirals era.
about
Molecular characterization and epidemic history of hepatitis C virus using core sequences of isolates from Central Province, Saudi Arabia.Antiviral Activity and Resistance Analysis of NS3/4A Protease Inhibitor Grazoprevir and NS5A Inhibitor Elbasvir in Hepatitis C Virus GT4 Replicons.Sofosbuvir Plus Daclatasvir in Treatment of Chronic Hepatitis C Genotype 4 Infection in a Cohort of Egyptian Patients: An Experiment the Size of Egyptian Village.
P2860
Management of hepatitis C genotype 4 in the directly acting antivirals era.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 30 September 2016
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Management of hepatitis C genotype 4 in the directly acting antivirals era.
@en
Management of hepatitis C genotype 4 in the directly acting antivirals era.
@nl
type
label
Management of hepatitis C genotype 4 in the directly acting antivirals era.
@en
Management of hepatitis C genotype 4 in the directly acting antivirals era.
@nl
prefLabel
Management of hepatitis C genotype 4 in the directly acting antivirals era.
@en
Management of hepatitis C genotype 4 in the directly acting antivirals era.
@nl
P2860
P1476
Management of hepatitis C genotype 4 in the directly acting antivirals era.
@en
P2093
Ahmed M Elsharkawy
Emma Hathorn
P2860
P304
P356
10.1136/BMJGAST-2016-000112
P577
2016-09-30T00:00:00Z